Doctors and patients are always looking to identify ways to tell if cancer treatments are working. A new study sugggests that in patients with advanced kidney (renal) cancer who are taking the kinase inhibitor sunitinib (Nexavar®), their blood pressure may be a good marker. The researchers examined records from clinical trials of sunitinib and found that those patient who had high blood pressure had a better responses and survival than patients whose blood pressure was not elevated. Importantly, the patients did not have increased incidence of problems associated with high blood pressure.
Learn More
Top